Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors

Arsenic cardiotoxicity: An overview

(2015) Nafiseh Sadat Alamolhodaei et al.   ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY

Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin’s lymphoma: an in vitro and in vivo study

(2015) Jin Sun Yoon et al.   INVESTIGATIONAL NEW DRUGS

KML001 Displays Vascular Disrupting Properties and Irinotecan Combined Antitumor Activities in a Murine Tumor Model

(2013) Chang Hoon Moon et al.   PLoS One

KML001 Cytotoxic Activity Is Associated with Its Binding to Telomeric Sequences and Telomere Erosion in Prostate Cancer Cells

(2008) P. Phatak et al.   CLINICAL CANCER RESEARCH

Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials

(2008) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

Oxidation state specific generation of arsines from methylated arsenicals based on l-cysteine treatment in buffered media for speciation analysis by hydride generation-automated cryotrapping-gas chromatography-atomic absorption spectrometry with the multiatomizer

(2007) Tomáš Matoušek et al.   SPECTROCHIMICA ACTA PART B-ATOMIC SPECTROSCOPY